VBI Vaccines (NASDAQ:VBIV) Trading Down 4.5%

Share on StockTwits

VBI Vaccines Inc (NASDAQ:VBIV) traded down 4.5% during trading on Tuesday . The stock traded as low as $0.81 and last traded at $0.86, 3,722,836 shares were traded during trading. An increase of 122% from the average session volume of 1,678,684 shares. The stock had previously closed at $0.91.

A number of equities research analysts recently weighed in on VBIV shares. Raymond James started coverage on shares of VBI Vaccines in a research note on Thursday, November 14th. They issued an “outperform” rating and a $3.00 target price on the stock. Zacks Investment Research lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. VBI Vaccines presently has an average rating of “Buy” and a consensus price target of $3.81.

The firm has a market cap of $160.13 million, a P/E ratio of -0.81 and a beta of 0.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.88 and a quick ratio of 1.84. The stock has a 50 day moving average of $0.63 and a 200 day moving average of $0.88.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.02). VBI Vaccines had a negative net margin of 1,458.97% and a negative return on equity of 70.54%. The firm had revenue of $0.65 million for the quarter, compared to analysts’ expectations of $0.90 million. On average, research analysts predict that VBI Vaccines Inc will post -0.47 EPS for the current fiscal year.

In other VBI Vaccines news, CEO Jeff Baxter acquired 150,000 shares of the stock in a transaction dated Monday, September 30th. The stock was purchased at an average cost of $0.50 per share, for a total transaction of $75,000.00. Following the acquisition, the chief executive officer now owns 608,255 shares in the company, valued at approximately $304,127.50. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Steven Gillis acquired 10,000,000 shares of the business’s stock in a transaction dated Thursday, September 19th. The stock was acquired at an average cost of $0.50 per share, with a total value of $5,000,000.00. Insiders have bought a total of 30,212,000 shares of company stock worth $15,105,440 over the last quarter. Corporate insiders own 10.50% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. General American Investors Co. Inc. boosted its position in VBI Vaccines by 23.2% during the second quarter. General American Investors Co. Inc. now owns 2,174,264 shares of the biopharmaceutical company’s stock valued at $2,544,000 after buying an additional 409,800 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of VBI Vaccines in the second quarter worth about $25,000. Bank of Montreal Can lifted its stake in shares of VBI Vaccines by 71.8% in the 2nd quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 15,717 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of VBI Vaccines by 664.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 200,848 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 174,576 shares during the last quarter. Finally, Fosun International Ltd boosted its holdings in VBI Vaccines by 43.6% during the 2nd quarter. Fosun International Ltd now owns 1,051,126 shares of the biopharmaceutical company’s stock valued at $1,156,000 after acquiring an additional 319,045 shares during the period. Institutional investors own 40.91% of the company’s stock.

About VBI Vaccines (NASDAQ:VBIV)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Read More: Technical Analysis

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.